The average P/S ratio for MIRM's competitors is 5.70, providing a benchmark for relative valuation. Mirum Pharmaceuticals Inc Corp (MIRM) exhibits a P/S ratio of 5.69, which is -0.12% above the industry average. Given its robust revenue growth of 61.20%, this premium appears sustainable.